FibroGen Inc. (FGEN) CEO Thomas B. Neff Sells 18,899 Shares
FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,899 shares of the firm’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $20.67, for a total value of $390,642.33. Following the completion of the transaction, the chief executive officer now owns 3,370,103 shares in the company, valued at approximately $69,660,029.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
FibroGen Inc. (NASDAQ:FGEN) opened at 20.73 on Thursday. The firm has a 50-day moving average price of $19.60 and a 200 day moving average price of $18.68. FibroGen Inc. has a 1-year low of $14.38 and a 1-year high of $31.90. The firm’s market cap is $1.30 billion.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by $0.01. FibroGen had a negative return on equity of 48.66% and a negative net margin of 61.90%. Equities analysts predict that FibroGen Inc. will post ($1.25) earnings per share for the current year.
Several institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in FibroGen during the second quarter worth approximately $106,000. Acrospire Investment Management LLC boosted its position in FibroGen by 240.2% in the second quarter. Acrospire Investment Management LLC now owns 6,657 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 4,700 shares during the period. Teacher Retirement System of Texas boosted its position in FibroGen by 15.7% in the second quarter. Teacher Retirement System of Texas now owns 6,891 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 937 shares during the period. Quantbot Technologies LP acquired a new position in FibroGen during the second quarter worth approximately $164,000. Finally, Fox Run Management L.L.C. acquired a new position in FibroGen during the second quarter worth approximately $176,000. 49.82% of the stock is owned by institutional investors.
Separately, Credit Suisse Group AG reiterated a “buy” rating on shares of FibroGen in a report on Tuesday, July 12th.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.